HDAC4 and neoplasm: Assuming that cellular uptake and metabolism are likewise not limiting the action of the novel hydroxamic acid compounds, the discrepancy between their in vitro IC50s for HDAC4/5 and their CC50 values on tumor cells suggests that inhibition of class IIA HDACs may not be responsible for the observed inhibition of cell proliferation.